Immune features of graft-derived mucosal-associated invariant T cells predict gastrointestinal graft-versus-host disease.
Three immune cell markers measured before transplant may help predict which patients will develop serious gut complications, enabling earlier intervention.
A 3-marker MAIT cell panel (CCR2, IL-4, IL-17A) achieves AUC 0.80 (0.85 adjusted) for pre-transplant prediction of GI acute graft-versus-host disease after allo-HSCT. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective observational study (spectral flow cytometry, ChiCTR2500095349)
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- Br J Haematol
Why it surfaced
Prospective study with registered clinical trial demonstrating MAIT cells as a validated pre-transplant risk biomarker for GI aGVHD (AUC 0.85), a major cause of transplant morbidity and mortality.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.